ライフサイエンスコーパス: glucose level

1 t graft loss observed via uncontrolled blood glucose level.

2 d glucose tolerance and down-regulated blood glucose level.

3 points included the change in fasting plasma glucose level.

4 cardiometabolic outcomes, including fasting glucose level.

5 lin secretion in response to increased brain glucose level.

6 enabling potential seamless control of blood glucose level.

7 index, systolic blood pressure, and fasting glucose level.

8 s play an essential role in regulating blood glucose level.

9 onse catabolic or unresponsive to increasing glucose levels.

10 not counter leptin's ability to lower blood glucose levels.

11 ufficient insulin to properly regulate blood glucose levels.

12 ecretion and maintaining physiological blood glucose levels.

13 less of their cholesterol ratios and fasting glucose levels.

14 ly attributed to the latency of interstitial glucose levels.

15 n irreversible and progressive drop of blood glucose levels.

16 moking status, body mass index, and baseline glucose levels.

17 h undergo exocytosis upon elevation of blood glucose levels.

18 enous Glut is modulated by plasma and tissue glucose levels.

19 lectively, these changes can normalise blood glucose levels.

20 hibitory, in glucagon secretion depending on glucose levels.

21 ffects on food intake, body weight and blood glucose levels.

22 n index) and the elevation of fasting or 2-h glucose levels.

23 es in the liver and kidney to maintain blood glucose levels.

24 thereby linking insulin secretion to plasma glucose levels.

25 bolic bistable region with respect to plasma glucose levels.

26 rides, might have a causal role of elevating glucose levels.

27 c low-grade inflammation and elevated plasma glucose levels.

28 There was no difference in glucose levels.

29 inated upon exposure of beta-cells to normal glucose levels.

30 ple, blood permittivity depends on the blood glucose levels.

31 Institutes of Health Stroke Scale score, and glucose levels.

32 , increase glucose excretion and lower blood glucose levels.

33 ches, leading to a gradual decrease in blood glucose levels.

34 were equally efficacious in reducing plasma glucose levels.

35 dinates transcriptional response to elevated glucose levels.

36 f glucagon and insulin at basal and elevated glucose levels.

37 olymorphisms, circulating CRP, diabetes, and glucose levels.

38 ecreased alpha-cell function, and thus lower glucose levels.

39 coupled receptor (GPCR) that regulates blood glucose levels.

40 preoperative HbA1c levels and postoperative glucose levels.

41 l, high-density lipoprotein cholesterol, and glucose levels.

42 stasis of hepatic glycogen storage and blood glucose levels.

43 s effects to raise BP and reduce insulin and glucose levels.

44 e number of free islets was unable to affect glucose levels.

45 as those guided by physicians in controlling glucose levels.

46 evel, high total cholesterol level, and high glucose levels.

47 tween defective insulin secretion and rising glucose levels.

48 in the DIO model and increased fasting blood glucose levels.

49 mpathetic cholinergic fibers increases blood glucose levels.

50 od samples were analyzed for cholesterol and glucose levels.

51 esis, glucose intolerance, and fasting blood glucose levels.

52 sed adiposity and decreased control of blood glucose levels.

53 vivo and access to the blood for monitoring glucose levels.

54 mpanied by an increase in saliva lactate and glucose levels.

55 satisfaction are linked to changes in blood glucose levels.

56 mic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma gluco

57 nce test in mice, fraction 16C reduced blood glucose level (181 +/- 10 mg/dL) in comparison to the ve

58 e level, 100 to 125 mg per deciliter; plasma glucose level 2 hours after a 75-g oral glucose load, 14

59 insulin therapy (IIT) targeting normal blood glucose levels (81-108 mg/dl) increases the incidence of

60 STZ-treated rats displayed an increase in glucose levels, a decrease in body weight, and an increa

61 gR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin le

62 Mechanistically, high glucose levels activate a specific positive Delta-like 4

63 ntly, NT-ES-beta-cells maintain normal blood glucose levels after ablation of the mouse endogenous be

64 0.20; 95% CI, 0.02 to 0.38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hed

65 ing on fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fas

66 esponses (P=0.03-0.001) and decreased plasma glucose levels after glucose ingestion (P=0.02) with mor

67 A lowered blood glucose level also was observed in overnight-fasted, str

68 HbA1c for given levels of fasting or 2-hour glucose levels among African Americans.

69 erations (MO), was associated with increased glucose levels among the civilian population.

70 Data on 2-hour plasma glucose level and HbA1c concentration were not available

71 splay resistance to T1D as the rise in blood glucose level and islet inflammation were significantly

72 Offspring exhibited similar weight, blood glucose levels and baseline water and chow intake in adu

73 that hepatic GCN5L1 ablation reduces fasting glucose levels and blunts hepatic gluconeogenesis withou

74 diabetes drug, dapagliflozin, reduces blood glucose levels and body weight by inhibiting sodium gluc

75 agnosis of NDH and T2D, and changes in blood glucose levels and cardiovascular risk score between ind

76 Blood glucose levels and disease severities were analyzed.

77 h PM2.5 exposure during pregnancy with blood glucose levels and GDM risk in Chinese women.

78 .5 exposure during pregnancy increases blood glucose levels and GDM risk in Chinese women.

79 e in the NAc bidirectionally modulated blood glucose levels and glucose tolerance.

80 licate NAc D2R in regulating both peripheral glucose levels and glucose-dependent reinforcement learn

81 uence resulted in a reduction in basal blood glucose levels and increased circulating serum insulin a

82 we show that 13d significantly lowers blood glucose levels and increases concomitant beta-cell survi

83 ivo, constitutively active YAP lowers plasma glucose levels and increases liver size.

84 Although near-normal glucose levels and insulin independence can be maintaine

85 es hallmarks of diabetes, including elevated glucose levels and intolerance to dietary sugars.

86 ize phenylacetaldehyde was achieved for high glucose levels and low amounts of gallic acid and metals

87 oring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypogly

88 h energetic stress and are vulnerable to low glucose levels and metformin.

89 Longitudinal changes in bodyweight, blood glucose levels and plasma insulin concentration were als

90 exhibited significantly higher fasting blood glucose levels and produced more glucose than floxed AMP

91 fruit fly brain that directly senses 'blood' glucose levels and reciprocally regulates the secretion

92 verted "U-shape" fashion dependent on plasma glucose levels and related to metabolic states.SIGNIFICA

93 ittent fasting as a strategy to reduce tumor glucose levels and sensitize otherwise resistant tumor c

94 tilization, orchestrated by modifications in glucose levels and the glucagon/insulin ratio in the blo

95 s of age, high total cholesterol level, high glucose level, and abdominal subcutaneous fat were inclu

96 circumference, hypertension, elevated plasma glucose level, and dyslipidemia).

97 stroke program early CT score (ASPECTS), and glucose level, and from these predictors, we derived the

98 eration, hepatic inflammation, fasting blood glucose level, and glucose intolerance, compared with th

99 esponsiveness, admission Glasgow Coma Scale, glucose level, and hemoglobin level) and used in univari

100 and age, high total cholesterol level, high glucose level, and subcutaneous fat.

101 sity lipoprotein cholesterol levels, fasting glucose levels, and adiposity at 12 to 24 months' follow

102 erproinsulinemia is independent of age, sex, glucose levels, and endoplasmic reticulum-CCAAT enhancer

103 several metabolic parameters including blood glucose levels, and insulin and glucose tolerance.

104 recast decision indicates blood pressure and glucose level are key features for diabetes.

105 ced at TNZ, while its effects on insulin and glucose levels are attenuated and its effects on BP and

106 revious work in prostate cancer showing that glucose levels are high while citrate is low, we found t

107 ppressing the release of AKH when haemolymph glucose levels are high.

108 When glucose levels are limited, ketone bodies generated in t

109 ctivity persist, and relatively normal blood glucose levels are maintained.

110 tive hemoglobin A1c (HbA1c) or postoperative glucose levels are more useful in predicting adverse eve

111 Blood glucose levels are tightly controlled by the coordinated

112 The premise is that chronically elevated glucose levels are toxic to beta-cells, that elevated li

113 te of tendon degeneration persists even when glucose levels are well controlled, suggesting that othe

114 te, and non-invasive monitoring of the blood glucose level as an effective technique for diabetes con

115 ogy now allows real time monitoring of blood glucose levels as a time series, and thus the exploratio

116 recise dosing in response to real-time blood glucose levels as well as a feasible and low-burden admi

117 % degree of gelatinization and maximal blood glucose level at 30min).

118 n ( approximately 53.8%) and a maximal blood glucose level at 60min (slower glycemic response) than a

119 evels at 60' were positively associated with glucose levels at 60 min (r = 0.55, p = 0.01 and r = 0.4

120 Higher blood glucose levels at admission and during the first 36 hour

121 in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group.

122 the range of Glc-1 to Glc-20 and high blood glucose level being retained in greater quantity.

123 s of severe hypoglycemia, defined as a blood glucose level below 40 mg per deciliter (2.2 mmol per li

124 2.2 +/- 0.44 kg/m(2) in persons with fasting glucose levels below and above the median, respectively.

125 this, with a steeper increase of the fasting glucose level (beta=131; 95% CI 38-225) during follow-up

126 lin, glargine, resulted in fluctuating blood glucose levels between 91 and 443 mg/dL in type 1 diabet

127 Elevated blood glucose level (BGL) and NLR were strongly associated wit

128 bility and a remarkable sensitivity of blood glucose levels (BGLs).

129 CREBH deficiency leads to reduced blood glucose levels but increases hepatic glycogen levels dur

130 46a1(-/-) mice that had normal fasting blood glucose levels but up to a 1.8-fold increase in retinal

131 cilitate rapid release in response to rising glucose levels, but the mechanisms by which these granul

132 xposure during trimester 2 increased fasting glucose level by 0.85% (95% CI: 0.41, 1.29).

133 ormal chow-fed mice showed upregulated blood glucose level by increasing gluconeogenesis, and upregul

134 GLP-1 is capable of regulating the blood glucose level by insulin secretion after administration

135 rimester 1 increased 1-hour and 2-hour blood glucose levels by 1.40% (95% CI: 0.42, 2.37) and 1.82% (

136 Insulin regulates blood glucose levels by binding its receptor and stimulating d

137 y facilitates the maintenance of circulating glucose levels by decreasing the rate of blood sugar abs

138 city can be reversed by reducing circulating glucose levels by fasting or insulin.

139 ng small intestinal mTOR alone lowers plasma glucose levels by inhibiting glucose production in roden

140 T2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the

141 agon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose product

142 ers real-time information about interstitial glucose levels, by focusing on the challenges toward dev

143 Proper control of the blood glucose level can delay, and to a greater extent, preven

144 course of HSV infection and that modulating glucose levels can influence the outcome of infection, b

145 act of a given meal on an individual's blood glucose levels can serve as the engine for a new generat

146 , to stably and accurately control the blood glucose level, CGM should be stable and accurate for a l

147 t, we make the unexpected finding that blood glucose levels change significantly during the course of

148 waves in transmission mode that can measure glucose level changes based on the complex permittivity

149 was associated with increased postoperative glucose level checks and insulin use, suggesting that he

150 eeded biomaterial coupled with reduced blood glucose levels, collectively resulting in increased surv

151 Only 8% monitored their blood glucose levels daily, 15% monitored weekly, and 10% repo

152 roblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorated path

153 lotype had higher plasma CHGA levels, plasma glucose levels, diastolic blood pressure, and body mass

154 High glucose levels did not alter placental lipase or transpo

155 These results show that glucose levels directly regulate osteocyte function thro

156 ote, non-obese diabetic mice with high blood glucose levels displayed a healthy colonic mucus barrier

157 Interestingly, blood-glucose-levels drop severely in treated animals, presuma

158 lobe to measure the change in intracerebral glucose levels during a 2-h glucose clamp (target glucos

159 e insulin secretion to better regulate blood glucose levels during periods of changing metabolic dema

160 owth on pregnancy outcomes, maternal BP, and glucose levels during pregnancy.

161 Despite a similar change in plasma glucose levels during the hyperglycemic clamp, individua

162 ress to be associated with increased fasting glucose levels, especially among those who reside in loc

163 nal glucose change (P < 0.001), and baseline glucose levels explained 10% of variation (P < 0.0001).

164 d NADPH oxidase 4 expression induced by high glucose level exposure.

165 Glucose levels fluctuated during the day in both healthy

166 gives the stable and reliable value of blood glucose levels for a period of 90-120 days.

167 L to 3mmol/L, which covers the range of tear glucose levels for both diabetics and healthy subjects.

168 ssfully normalized and maintained host blood glucose levels for over 370 days in the absence of immun

169 glucose monitor for continuous monitoring of glucose levels for people living with diabetes, as it ca

170 f preoperative HbA1c and early postoperative glucose levels for predicting postoperative complication

171 lucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage

172 We defined diabetes as a fasting glucose level >/=126 mg/L (or >/=200 mg/L for those not

173 High glucose level (>/=6.11mmol/L) was associated with a lowe

174 The fasting plasma glucose level had decreased at both time points in the l

175 ht glycemic control targeting a normal blood glucose level has not been shown to improve outcomes in

176 d glucose sensors at lower than normal blood glucose levels has blocked their practical applications.

177 etection capability of the diabetes-spectrum glucose levels, has several other favorable attributes i

178 Fasting plasma glucose levels (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P

179 type 2 diabetes and poorly controlled blood glucose levels (hemoglobin A1c (HbA1c) levels of >7) als

180 nt gemcitabine (n = 107) with elevated serum glucose levels (HgbA1C > 6.5%) exhibited improved surviv

181 Lower fasting blood glucose levels, higher insulin, and lower islet amyloid

182 lycemic variability is associated with brain glucose levels highlight the need for future studies to

183 (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.39), and hyper

184 rmulation effectively lowered the high blood glucose level in a T2D db/db mice model to the normal ra

185 d to improve liver glycogen storage and sera glucose level in mice expressing human AATZ mice.

186 e also showed significant drops of the blood glucose level in rats derived from hypoglycemic activity

187 iochemical vital signs of health such as the glucose level in sweat has attracted increasing attentio

188 n the rat buccal pouch in vivo lowered blood glucose levels in a dose-dependent manner (up to 50% dro

189 n the fasting state is followed by increased glucose levels in both sweat and blood.

190 betes to determine whether cognition affects glucose levels in contrast to widely held suppositions.

191 ared as viable therapeutics to control blood glucose levels in diabetic patents.

192 e non-invasive and on-body quantification of glucose levels in human perspiration.

193 Finally, transplanted BAs reduce circulating glucose levels in hyperglycemic animals.

194 -specific GLUT4 expression and raised plasma glucose levels in LKO mice.

195 ompound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge,

196 sEPD of insulin was found to maintain blood glucose levels in normal range for at least 6h in chemic

197 cutaneous injection failed to maintain blood glucose levels in normal range.

198 neurons stimulated feeding while decreasing glucose levels in normoglycaemic mice.

199 uire daily insulin therapy to maintain blood glucose levels in normoglycemic ranges to prevent associ

200 haTSC2(KO) mice was associated with improved glucose levels in streptozotocin-induced beta-cell destr

201 ut retained its ability to lower circulating glucose levels in the absence of GDF15 activity.

202 ses from a dysregulated response to elevated glucose levels in the circulation.

203 streptozotocin-treated rats had lower brain glucose levels in the cortex, hippocampus, and striatum

204 exogenous insulin aimed at regulating blood glucose levels in the normoglycemic range.

205 d after beverage consumption show that blood glucose levels increase when participants believe the be

206 glucose administration under similar plasma glucose levels (incretin effect).

207 ets appear to be capable of regulating blood glucose levels independently from the central nervous sy

208 Loss of gpr27 potentiated the elevation in glucose levels induced by pharmacological or nutritional

209 We could show that glucose levels influenced the extent of induction of the

210 ER) stress related gene expressions, fasting glucose levels, insulin sensitivity and restored pancrea

211 in receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in o

212 Tracking the fluctuations in blood glucose levels is important for healthy subjects and cru

213 Although liraglutide decreased glucose levels, it did not restore complexity in diabeti

214 ater (>/=225 mg/dL) (hyperglycemic) and/or a glucose level less than 3.9 mmol/L (<70 mg/dL) (hypoglyc

215 Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes p

216 LQT2 patients developed hypoglycemic plasma glucose levels (<70 mg/dL) versus 36% control participan

217 hypoglycemia with severity of level 2 (blood glucose level, <54 mg per deciliter) or level 3 (severe

218 Higher fasting glucose levels may amplify obesity-risk in FTO carriers

219 Blood glucose levels measured four times before and after beve

220 sor as a possible candidate for non-invasive glucose levels monitoring for diabetes as evidenced by t

221 idome between participants with normal blood glucose levels (n = 26) and those with type 2 diabetes (

222 vascular risk factors such as abnormal blood glucose levels, obesity, and smoking are not included in

223 rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter

224 m tight glycemic control targeted to a blood glucose level of 80 to 110 mg per deciliter, as compared

225 Diabetes was defined as a random glucose level of at least 200 mg/dL, hemoglobin A1c conc

226 orily, which is well below the typical human glucose levels of 4 mmol/l.

227 detection compatible with interstitial fluid glucose levels of diabetic patients and b) effect of sam

228 ow proved compatible with interstitial fluid glucose levels of diabetic patients.

229 t and procedural factors, peak postoperative glucose levels of more than 250 mg/dL were associated wi

230 pporting NHANES analyses showed that fasting glucose levels of obese adults were inversely related to

231 insufficient insulin secretion and elevated glucose levels, often in combination with high levels of

232 Here, the effects of high glucose levels on influenza severity were investigated u

233 yte-like cell line to examine the effects of glucose levels on osteocyte function and viability in vi

234 es vary significantly, irrespective of blood glucose level or diabetic status.

235 ria are present - 'D', either elevated blood glucose levels or a family history of diabetes mellitus;

236 with lung function, haemoglobin, creatinine, glucose levels or resting blood pressure measures.

237 e hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes to behavioral counseling to

238 The level of HbA1c reflects the mean blood glucose level over the prior 2-3 months and it is useful

239 ed daily food intake, body weight, and blood glucose levels over a 3-week period.

240 nd lipid metabolism, associated with fasting glucose level (P = 1.80 x 10(-8)).

241 ficantly smaller increments in intracerebral glucose levels (P = 0.0002).

242 perienced a reduction of 8.61 mg/dL in their glucose levels (p = 0.005) and 0.34% in their HbA1c leve

243 y overweight (p = 0.046), had higher fasting glucose levels (p = 0.037), better scores at the Clock D

244 r allele of rs11932595 showed higher fasting glucose levels (p = 0.044) and better scores at CDT (p =

245 -control studies reporting on fasting plasma glucose levels, plasma glucose levels after an oral gluc

246 on models adjusting for HbA1c, postoperative glucose levels, postoperative insulin use, diabetes, bod

247 ies seldom focus precisely on maternal blood glucose level prior to pregnancy.

248 In contrast to the RSS1 and RSS3 conditions, glucose levels reduced more quickly for the DSS conditio

249 ase of exendin-4, prolonged control of blood glucose level, reduced dosing frequency, and improved pa

250 se concentrations in the circulation whereas glucose levels remained elevated in both single cultures

251 associated with type 2 diabetes and fasting glucose levels reside in introns of ADCY5, a gene that e

252 d by systolic blood pressure (SBP) and blood glucose levels, respectively.

253 ere birth defects and can be induced by high glucose levels resulting from maternal diabetes.

254 promoted weight gain without altering blood glucose levels, silencing VMNCCKBR neurons decreased hIe

255 ns, increased BP status or the fasting serum glucose level status were associated with cancer risk in

256 d levels of total cholesterol, and increased glucose levels, supporting previous findings that MARC2

257 ealth state of the animals with normal blood glucose levels (Table 1).

258 ing the scans (e.g., fasting vs. nonfasting, glucose levels, temperature regulation vs. constant temp

259 ing melanocortinergic pathway elevates blood glucose levels that is associated with increased express

260 to secrete insulin in response to increased glucose levels that occur with eating.

261 blood pressure and totally independent from glucose levels, that lead to cerebrovascular disease.

262 dependent of cholesterol, triglycerides, and glucose levels, the %PC 38:3-PWD association was mediate

263 While at normal glucose levels, the release of insulin is practically pr

264 tion achieved a rapid reduction of the blood glucose level to the normal range within <12 h and maint

265 Moreover, GLP1(HepoK) decreased blood glucose level to the same level as GLP1(WT) in mice, sho

266 acid also amplified the effects of elevated glucose levels to stimulate hepatocyte triglyceride accu

267 DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significa

268 The authors demonstrate that high blood glucose levels trigger neutrophil release of S100 calciu

269 in (HDL) cholesterol level, impaired fasting glucose level, type 2 diabetes mellitus, hypertension (H

270 channel shows obvious patterns that reflect glucose-level variations.

271 Empagliflozin reduces blood glucose levels via inhibition of the sodium glucose cotr

272 ondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose le

273 lobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per dec

274 During treatment, the mean blood glucose level was 118 mg/dL (6.6 mmol/L) in the intensiv

275 The target blood glucose level was 90-120 mg/dL for patients admitted bef

276 oups, the median percentage of time that the glucose level was below 70 mg per deciliter was low (1.6

277 involving children with type 1 diabetes, the glucose level was in the target range for a greater perc

278 outcome was the percentage of time that the glucose level was in the target range of 70 to 180 mg pe

279 The mean (+/-SD) percentage of time that the glucose level was in the target range of 70 to 180 mg pe

280 ol) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.

281 The blood glucose level was maintained to below the therapeutic le

282 performance in prediction of fasting plasma glucose level was measured using 100 bootstrap iteration

283 Association analysis showed that glucose level was positively associated with Digital Seq

284 each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec gr

285 l analyses, the median time-weighted average glucose level was significantly lower in the lower-targe

286 The mean (+/-SD) percentage of time that the glucose level was within the target range increased in t

287 me was the percentage of time that the blood glucose level was within the target range of 70 to 180 m

288 ng subjects who reside in proximity to Gaza, glucose levels were 2.10% (95% CI 1.24%; 2.97%) higher i

289 g diabetes, several combinations of abnormal glucose levels were associated with increased 90-day mor

290 in levels, body weight and blood vitamin and glucose levels were determined.

291 increase in the HDL/LDL ratio, and improved glucose levels were documented.

292 Remarkably, retinal glucose levels were elevated 50-fold, consistent with de

293 As expected, pre-diagnostic blood glucose levels were inversely related to glioma risk (AM

294 Body weights, blood glucose levels were monitored throughout the study.

295 h lowered insulin secretion, increases serum glucose levels, which stimulates de novo lipogenesis (DN

296 rapy was designed to rapidly normalize blood glucose levels with bolus doses of insulin and rapid ins

297 Normalization of blood glucose levels with GCGR-blocking antibody unexpectedly

298 that G6P mutant flies exhibit low whole-body glucose levels within 24 h of food deprivation.

299 of this insulin conjugate to regulate blood glucose levels within a normal range while mitigating th

300 lin, causing a significant decrease in blood glucose levels within one hour.